Blog
RSS FeedPosted by Michael Wonder on 22 Aug 2019
Gilead files challenge to government patents for HIV prevention pill
21 August 2019 - Gilead Sciences took the unusual step of mounting a challenge to U.S. government patents on Wednesday, ...
Posted by Michael Wonder on 26 Jun 2019
Novartis wins Gilenya reprieve as judge blocks generics, for now
25 June 2019 - Novartis has won a U.S. federal court order preventing rival generic makers from selling versions of the ...
Posted by Michael Wonder on 08 May 2019
They were supposed to talk about the patent system driving up drug prices. But most lawmakers got distracted by small tweaks.
7 May 2019 - If there was any hope that Congress might overhaul the way this country doles out the ...
Posted by Michael Wonder on 11 Feb 2019
‘One-and-done’ for new drugs could cut patent thickets and boost generic competition
11 February 2019 - In a perfect world, the system for conveying medications from their makers to patients should be ...
Posted by Michael Wonder on 08 Dec 2018
Patent abuse is driving up drug prices. Just look at Lantus.
7 December 2018 - A rare point of consensus following the midterm elections is that Americans are adamant about lowering ...
Posted by Michael Wonder on 19 Oct 2018
Competition watchdog’s appeal over Pfizer ruling dismissed
19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...
Posted by Michael Wonder on 19 Oct 2018
AbbVie announces global resolution of Humira (adalimumab) patent disputes with Fresenius Kabi
18 October 2018 - Agreements provide non-exclusive license to Fresenius Kabi for Humira related intellectual property in the U.S. effective 30 ...
Posted by Michael Wonder on 19 Sep 2018
Truvada ruling could allow cheap HIV prevention in the UK
19 September 2018 - Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk ...
Posted by Michael Wonder on 13 Aug 2018
Promoting patient interests in implementing the Federal Right to Try Act
13 August 2018 - On May 30, 2018, President Trump signed into law the federal Right to Try Act of 2017,1 ...
Posted by Michael Wonder on 08 Nov 2017
Paediatric exclusivity and regulatory authority
8 November 2017 - In May 2017, the US FDA denied a 6-month extension of market exclusivity for Sensipar (cinacalcet), ...
Posted by Michael Wonder on 04 May 2017
Another small victory for Australian Government in its pursuit of damages for PBS over-payments during interlocutory injunction period
4 May 2017 - The Australian Government has had another small victory in the most recent interlocutory decision in the clopidogrel ...
Posted by Michael Wonder on 26 Apr 2017
Changes to pharmaceutical extension of term application procedures the latest front in the battle for savings in Australia’s health care budget
26 April 2017 - It’s no secret that the Australian Government is struggling to manage the cost of its health ...
Posted by Michael Wonder on 20 Apr 2017
Full Federal Court confirms an application to list medicine on the PBS prior to patent expiry is a non-infringing act
19 April 2017 - Late last week, the Full Federal Court of Australia confirmed that the mere act of filing a ...
Posted by Michael Wonder on 10 Apr 2017
How patent trolls sparked a failed assault on high drug prices
11 April 2017 - Kyle Bass caused high anxiety for big pharma. ...
Posted by Michael Wonder on 10 Apr 2017
Bass battled U.S. drug patents and prices but lost to ‘Cabal’
10 April 2017 - Hedge fund manager says he raised awareness of high drug costs. ...